HC Wainwright & Co. Reiterates Buy on Crinetics Pharmaceuticals, Maintains $35 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Crinetics Pharmaceuticals (NASDAQ:CRNX) and maintained a $35 price target.
June 08, 2023 | 10:39 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Crinetics Pharmaceuticals (NASDAQ:CRNX) receives a reiterated Buy rating and a maintained $35 price target from HC Wainwright & Co. analyst Douglas Tsao.
The reiterated Buy rating and maintained $35 price target by HC Wainwright & Co. analyst Douglas Tsao indicates a positive outlook for Crinetics Pharmaceuticals. This news is likely to have a positive impact on the stock price in the short term as it reaffirms the analyst's confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100